Jiangxi Synergy Pharmaceutical Co Ltd Total Assets
Jiangxi Synergy Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Jiangxi Synergy Pharmaceutical Co Ltd (300636) holds total assets worth CN¥3.31 Billion CNY (≈ $484.59 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Jiangxi Synergy Pharmaceutical Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Jiangxi Synergy Pharmaceutical Co Ltd (2012–2025)
Total assets of Jiangxi Synergy Pharmaceutical Co Ltd from 2012 to 2025. This chart illustrates how Jiangxi Synergy Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Jiangxi Synergy Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
Jiangxi Synergy Pharmaceutical Co Ltd - Asset Composition Analysis
Jiangxi Synergy Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Jiangxi Synergy Pharmaceutical Co Ltd total assets breakdown as of December 2025. Jiangxi Synergy Pharmaceutical Co Ltd's total assets of CN¥3.31 Billion consist of 44.0% current assets and 56.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.6% |
| Accounts Receivable | CN¥117.83 Million | 3.6% |
| Inventory | CN¥510.45 Million | 15.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥18.75 Million | 0.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Jiangxi Synergy Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Jiangxi Synergy Pharmaceutical Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangxi Synergy Pharmaceutical Co Ltd's current assets represent 44.0% of total assets in 2025, an increase from 41.8% in 2012.
- Cash Position: Cash and equivalents constituted 7.6% of total assets in 2025, up from 4.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 15.4% of total assets.
Jiangxi Synergy Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangxi Synergy Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
Jiangxi Synergy Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.82 | 1.98 | 2.16 |
| Quick Ratio | 1.15 | 1.03 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥645.88 Million | CN¥576.48 Million | CN¥331.28 Million |
Jiangxi Synergy Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangxi Synergy Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | CN¥3.32 Billion |
| Market Capitalization | $400.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangxi Synergy Pharmaceutical Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jiangxi Synergy Pharmaceutical Co Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jiangxi Synergy Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual total assets of Jiangxi Synergy Pharmaceutical Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.32 Billion ≈ $485.97 Million |
+0.04% |
| 2024-12-31 | CN¥3.32 Billion ≈ $485.75 Million |
+3.05% |
| 2023-12-31 | CN¥3.22 Billion ≈ $471.40 Million |
+42.61% |
| 2022-12-31 | CN¥2.26 Billion ≈ $330.54 Million |
+18.47% |
| 2021-12-31 | CN¥1.91 Billion ≈ $279.01 Million |
+29.92% |
| 2020-12-31 | CN¥1.47 Billion ≈ $214.77 Million |
+44.50% |
| 2019-12-31 | CN¥1.02 Billion ≈ $148.63 Million |
+26.39% |
| 2018-12-31 | CN¥803.62 Million ≈ $117.59 Million |
+11.26% |
| 2017-12-31 | CN¥722.28 Million ≈ $105.69 Million |
+72.40% |
| 2016-12-31 | CN¥418.96 Million ≈ $61.31 Million |
+20.17% |
| 2015-12-31 | CN¥348.64 Million ≈ $51.02 Million |
+35.50% |
| 2014-12-31 | CN¥257.30 Million ≈ $37.65 Million |
+9.29% |
| 2013-12-31 | CN¥235.43 Million ≈ $34.45 Million |
+24.68% |
| 2012-12-31 | CN¥188.82 Million ≈ $27.63 Million |
-- |
About Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-… Read more